Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.
Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.
The mean of analysts' price targets for Ligand (LGND) points to a 38.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...